share_log

Earnings Call Summary | CANSORTIUM INC(CNTMF.US) Q4 2023 Earnings Conference

Earnings Call Summary | CANSORTIUM INC(CNTMF.US) Q4 2023 Earnings Conference

業績電話會議摘要 | CANSORTIUM INC (CNTMF.US) 2023 年第四季度業績發佈會
moomoo AI ·  04/29 21:46  · 電話會議

The following is a summary of the Cansortium Inc. (CNTMF) Q4 2023 Earnings Call Transcript:

以下是Cansortium Inc.(CNTMF)2023年第四季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Cansortium reported a Q4 increase in revenue by 9% to $25.5 million, mainly due to new dispensaries in Florida and higher patient counts.

  • The adjusted gross profit for the quarter was 49.4% of revenue, reaching $12.6 million.

  • Positive cash flow from operations was reported for the ninth consecutive quarter, amounting to $1.4 million in Q4.

  • The increased customer transactions throughout 2023 resulted in Adjusted EBITDA of $27.2 million, compared to $25 million in the previous year.

  • Cansortium報告稱,第四季度收入增長了9%,達到2550萬美元,這主要是由於佛羅里達州的新藥房和患者人數的增加。

  • 本季度調整後的毛利爲收入的49.4%,達到1,260萬美元。

  • 連續第九個季度報告了正的運營現金流,第四季度爲140萬美元。

  • 2023年全年客戶交易量的增加使調整後的息稅折舊攤銷前利潤爲2720萬美元,而去年同期爲2500萬美元。

Business Progress:

業務進展:

  • Cansortium opened four new dispensaries in Florida during 2023, anticipating potential expansion into the adult-use market.

  • The company witnessed substantial growth in the Texas market, credited to increases in retail volume and patient growth, predominantly in the Houston area.

  • Cansortium initiated strategic partnerships with wholesale suppliers in Pennsylvania, making them competitively priced in the market.

  • Development plans include opening an education center in Houston by 2025 and the expected operational contribution from the 'Rosa' facility in Q4 2024.

  • 2023年,Cansortium在佛羅里達州開設了四家新藥房,預計有可能向成人用途市場擴張。

  • 該公司見證了德克薩斯州市場的大幅增長,這要歸功於零售量的增加和患者增長,主要集中在休斯敦地區。

  • Cansortium與賓夕法尼亞州的批發供應商建立了戰略合作伙伴關係,使其在市場上具有競爭力的價格。

  • 發展計劃包括到2025年在休斯敦開設教育中心,以及 “羅莎” 設施預計在2024年第四季度提供的運營捐款。

More details: CANSORTIUM INC IR

更多詳情: CANSORTIUM INC IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論